Application consensus of peripheral blood <italic style="font-style: italic">HER</italic>2 gene amplification detection (digital PCR) in anti-HER2 therapy

Renquan LU; Guangyu LIU; Wentao YANG; Lin GUO; Ming GUAN; Zhimin SHAO; Dazhi XU; Ming NI; Feng TANG; Chaofu WANG; Jiatao LOU; Fenyong SUN; Jinliang XING; Yueyin PAN

doi:10.19401/j.cnki.1007-3639.2022.01.012

您当前的位置：

首页 >

文章列表页 >

Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy

Guideline and Consensus | 更新时间：2025-12-31

- Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
- China Oncology Vol. 32, Issue 1, Pages: 90-96(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.01.012
  CLC： R737.9
- Received：17 November 2021，
  
  Revised：2021-12-29，
  
  Published：30 January 2022
- 稿件说明：
移动端阅览
Renquan LU, Guangyu LIU, Wentao YANG, et al. Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy[J]. China Oncology, 2022, 32(1): 90-96.
DOI：

Renquan LU, Guangyu LIU, Wentao YANG, et al. Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy[J]. China Oncology, 2022, 32(1): 90-96. DOI： 10.19401/j.cnki.1007-3639.2022.01.012.

摘要

Abstract

关键词

Keywords

references

中国医药教育协会乳腺癌个案管理师分会 . 乳腺癌靶向药物静脉输注规范专家共识 [J ] . 中华医学杂志 , 2021 , 101 ( 16 ): 1143 - 1148 .

China Association for Breast Cancer Case Management Division . Consensus on guidelines for intravenous infusion of targeted drugs in breast cancer [J ] . Natl Med J China , 2021 , 101 ( 16 ): 1143 - 1148 .

江泽飞 , 邵志敏 , 徐兵河 . 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识 [J ] . 中华肿瘤杂志 , 2010 , 32 ( 2 ): 158 - 160 .

JIANG ZEFEI , SHAO ZHIMIN , XU BINGHE . Consensus on clinical diagnosis and treatment of human epidermal growth factor receptor 2 positive breast cancer [J ] . Chin J Oncol , 2010 , 32 ( 2 ): 158 - 160 .

中国临床肿瘤学会乳腺癌专家委员会 , 中国抗癌协会乳腺癌专业委员会 . 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版) [J ] . 中华医学杂志 , 2021 , 8 ( 17 ): 1226 - 1231 .

Breast Cancer Expert Committee of Chinese Society of Clinical Oncology , Breast Cancer Professional Committee of Chinese Anti-Cancer Association . Consensus on clinical diagnosis and treatment of human epidermal growth factor receptor 2 positive breast cancer (2021 edition) [J ] . Natl Med J China , 2021 , 8 ( 17 ): 1226 - 1231 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会乳腺癌诊疗指南2019 [M ] . 北京 : 人民卫生出版社 , 2019 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . The breast cancer guidelines 2019 of Chinese Society of Clinical Oncology [M ] . Beijing : People’s Med Publ House , 2019 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会乳腺癌诊疗指南2020 [M ] . 北京 : 人民卫生出版社 , 2019 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . The breast cancer guidelines 2020 of Chinese Society of Clinical Oncology [M ] . Beijing : People’s Med Publ House , 2019 .

《乳腺癌 HER 2检测指南(2019版)》编写组 . 乳腺癌 HER 2检测指南(2019版) [J ] . 中华病理学杂志 , 2019 , 48 ( 3 ): 169 - 175 .

Guideline for HER 2 detection of breast cancer (2019 edition) compiling group . Guideline for HER 2 detection of breast cancer (2019 edition)(2019版) [J ] . Chin J Pathol , 2019 , 48 ( 3 ): 169 - 175 .

WOLFF A C , HAMMOND M E H , ALLISON K H , et al. HER 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update summary [J ] . J Oncol Pract , 2018 , 14 ( 7 ): 437 - 441 . DOI: 10.1200/JOP.18.00206 http://doi.org/10.1200/JOP.18.00206 https://ascopubs.org/doi/10.1200/JOP.18.00206 https://ascopubs.org/doi/10.1200/JOP.18.00206

张众 , 王华新 , 谢丰培 . 乳腺癌异质性及其临床意义 [J ] . 临床与实验病理学杂志 , 2014 , 30 ( 5 ): 473 - 477 .

ZHANG Z , WANG H X , XIE F P . Heterogeneity of breast cancer and its clinical significance [J ] . Chin J Clin Exp Pathol , 2014 , 30 ( 5 ): 473 - 477 .

王歆光 , 刘毅强 , 何英剑 , 等 . 同侧多原发灶乳腺癌病灶间异质性的研究 [J ] . 中国癌症杂志 , 2017 , 27 ( 10 ): 809 - 814 .

WANG X G , LIU Y Q , HE Y J , et al. Intertumoral heterogeneity in patients with ipsilateral multifocal/multicentric breast cancer diagnosed by core needle biopsy [J ] . China Oncol , 2017 , 27 ( 10 ): 809 - 814 .

LOWER E E , GLASS E , BLAU R , et al. HER-2/neu expression in primary and metastatic breast cancer [J ] . Breast Cancer Res Treat , 2009 , 113 ( 2 ): 301 - 306 . DOI: 10.1007/s10549-008-9931-6 http://doi.org/10.1007/s10549-008-9931-6 http://link.springer.com/10.1007/s10549-008-9931-6 http://link.springer.com/10.1007/s10549-008-9931-6

HYUN C L , LEE H E , KIM K S , et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer [J ] . J Clin Pathol , 2007 , 61 ( 3 ): 317 - 321 . DOI: 10.1136/jcp.2007.050336 http://doi.org/10.1136/jcp.2007.050336 http://jcp.bmj.com/cgi/doi/10.1136/jcp.2007.050336 http://jcp.bmj.com/cgi/doi/10.1136/jcp.2007.050336

DAWSON S J , TSUI D W , MURTAZA M , et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer [J ] . N Engl J Med , 2013 , 368 ( 13 ): 1199 - 1209 . DOI: 10.1056/NEJMoa1213261 http://doi.org/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261

中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组 , 中国抗癌协会肿瘤标志专业委员会乳腺癌标志物协作组 . 复发/转移性乳腺癌标志物临床应用专家共识(2019年版) [J ] . 中国癌症防治杂志 , 2019 , 11 ( 5 ): 363 - 374 .

Genetic Tumor Markers Collaborative Group of Tumor Markers Professional Committee of China Anti-Cancer Association , Breast Cancer Markers Collaborative Group of Tumor Markers Professional Committee of China Anti-Cancer Association . Expert consensus on clinical application of markers for recurrent/metastatic breast cancer (2019 edition) [J ] . Chin J of Oncol Prev and Treat , 2019 , 11 ( 5 ): 363 - 374 .

徐兵河 , 王树森 , 江泽飞 , 等 . 中国晚期乳腺癌维持治疗专家共识 [J ] . 中华医学杂志 , 2018 , 98 ( 2 ): 87 - 90 .

XU B H , WANG S S , JIANG Z F , et al. Expert consensus on maintenance therapy for advanced breast cancer in China [J ] . Natl Med J China , 2018 , 98 ( 2 ): 87 - 90 .

ZHOU R F , YUAN P , ZHANG L H , et al. Using digital PCR to detect HER2 amplification in breast and gastric cancer patients [J ] . Front Lab Med , 2018 , 2 ( 3 ): 102 - 108 . DOI: 10.1016/j.flm.2018.11.002 http://doi.org/10.1016/j.flm.2018.11.002 https://linkinghub.elsevier.com/retrieve/pii/S2542364918300657 https://linkinghub.elsevier.com/retrieve/pii/S2542364918300657

WHALE A S , HUGGETT J F , COWEN S , et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation [J ] . Nucleic Acids Res , 2012 , 40 ( 11 ): e82 . DOI: 10.1093/nar/gks203 http://doi.org/10.1093/nar/gks203 https://academic.oup.com/nar/article/40/11/e82/2409772 https://academic.oup.com/nar/article/40/11/e82/2409772

母予馨 , 张频 , 马飞 , 等 . 乳腺癌原发灶和转移灶受体表达的异质性及其临床意义 [J ] . 中华肿瘤杂志 , 2018 , 40 ( 7 ): 506 - 511 .

MU Y X , ZHANG P , MA F , et al. Heterogeneity of receptor expression in primary and metastatic breast cancer and its clinical significance [J ] . Chin J Oncol , 2018 , 40 ( 7 ): 506 - 511 .

YI Z B , YU P , ZHANG S , et al. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study [J ] . Int J Cancer , 2021 , 148 ( 3 ): 692 - 701 . DOI: 10.1002/ijc.v148.3 http://doi.org/10.1002/ijc.v148.3 https://onlinelibrary.wiley.com/toc/10970215/148/3 https://onlinelibrary.wiley.com/toc/10970215/148/3

MA C X , BOSE R , GAO F , et al. Neratinib efficacy and circulating tumor DNA detection of HER 2 mutations in HER2 nonamplified metastatic breast cancer [J ] . Clin Cancer Res , 2017 , 23 ( 19 ): 5687 - 5695 . DOI: 10.1158/1078-0432.CCR-17-0900 http://doi.org/10.1158/1078-0432.CCR-17-0900 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0900 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0900

MA F , ZHU W J , GUAN Y F , et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy [J ] . Oncotarget , 2016 , 7 ( 40 ): 66020 - 66031 . DOI: 10.18632/oncotarget.v7i40 http://doi.org/10.18632/oncotarget.v7i40 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v7i40 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v7i40

GUAN X , LIU B , NIU Y , et al. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer [J ] . Breast , 2020 , 49 : 261 - 266 . DOI: 10.1016/j.breast.2019.12.010 http://doi.org/10.1016/j.breast.2019.12.010 https://linkinghub.elsevier.com/retrieve/pii/S0960977619312172 https://linkinghub.elsevier.com/retrieve/pii/S0960977619312172

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 , 中国抗癌协会胃癌专业委员会 , 中国抗癌协会肿瘤病理专业委员会 . HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版) [J ] . 临床肿瘤学杂志 , 2016 , 21 ( 9 ): 831 - 389 .

Expert Committee on Safety Management of Anti-Tumor Drugs of Chinese Society of Clinical Oncology , Gastric Cancer Professional Committee of China Anti-Cancer Association , Tumor Pathology Professional Committee of China Anti-Cancer Association . Chinese expert consensus on molecular targeted t her apy for HER2 positive advanced gastric cancer (2016 edition) [J ] . Chin Clin Oncol , 2016 , 21 ( 9 ): 831 - 389 .

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al. Trastuzumab in combination with chemotherapy versus chemot her apy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

TSURUTANI J , IWATA H , KROP I , et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase Ⅰ study in multiple advanced solid tumors [J ] . Cancer Discov , 2020 , 10 ( 5 ): 688 - 701 . DOI: 10.1158/2159-8290.CD-19-1014 http://doi.org/10.1158/2159-8290.CD-19-1014 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-19-1014 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-19-1014

HURVITZ S A , MARTIN M , SYMMANS W F , et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 1 ): 115 - 126 . DOI: 10.1016/S1470-2045(17)30716-7 http://doi.org/10.1016/S1470-2045(17)30716-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167 https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167

Views

3103

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Current status and future perspectives on consensus and controversies in advanced breast cancer for 2024

Important research progress in clinical practice for early breast cancer in 2024

Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China

Related Author

Hongxia WANG

Yongmei YIN

Xichun HU

Association Committee of Cancer Pain Fujian Anti-Cancer

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Tao WANG

Xiaobo WANG

Xinmiao YU

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital

Department of Breast Surgery, the First Affiliated Hospital of China Medical University

Department of Urology, Peking University Cancer Hospital

Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University

AI问答

⁰

Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy

DOI：10.19401/j.cnki.1007-3639.2022.01.012

摘要

Abstract

关键词

Keywords

references